AMENDMENT NO. 5 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • May 8th, 2013 • Targacept Inc • Pharmaceutical preparations
This Amendment No. 5 to Collaborative Research and License Agreement (this “Amendment”), effective as of the date of signature of the last Party to sign below, amends the Collaborative Research and License Agreement entered into as of December 27, 2005 by and between AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden (“AstraZeneca”), and Targacept, Inc., a Delaware (USA) corporation (“Targacept”), as amended by Amendment No. 1 dated November 10, 2006, Amendment No. 2 effective July 8, 2009, Amendment No. 3 effective April 30, 2010 and Amendment No. 4 effective September 28, 2010 (the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Agreement.
SEPARATION AGREEMENT AND RELEASESeparation Agreement and Release • May 8th, 2013 • Targacept Inc • Pharmaceutical preparations • North Carolina
This Separation Agreement and Release (this “Agreement”) is made by and between Jeffrey P. Brennan (“Brennan”) and Targacept, Inc. (“Targacept” or the “Company”), including all Targacept predecessor entities and all affiliated entities, and provides as follows.
